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Abstract
Complex I (CI) is the largest of the five multi-subunit complexes constituting the human oxidative phosphorylation
(OXPHOS) system. Seven of its catalytic core subunits are encoded by mitochondrial DNA (ND (NADH
dehydrogenase)1–6, ND4L (NADH dehydrogenase subunit 4L)), with mutations in all seven having been reported in
association with isolated CI deficiency. We investigated two unrelated adult patients presenting with marked
exercise intolerance, persistent lactic acidaemia and severe muscle-restricted isolated CI deficiency associated with
sub-sarcolemmal mitochondrial accumulation. Screening of the mitochondrial genome detected novel mutations in
the MTND1 (NADH dehydrogenase subunit 1) gene, encoding subunit of CI [Patient 1, m.3365T>C predicting
p.(Leu20Pro); Patient 2, m.4175G>A predicting p.(Trp290*)] at high levels of mitochondrial DNA heteroplasmy in
skeletal muscle. We evaluated the effect of these novel MTND1 mutations on complex assembly showing that CI
assembly, although markedly reduced, was viable in the absence of detectable ND1 signal. Real-time PCR and
Western blotting showed overexpression of different CI assembly factor transcripts and proteins in patient tissue.
Together, our data indicate that the mechanism underlying the expression of the biochemical defect may involve a
compensatory response to the novel MTND1 gene mutations, promoting assembly factor up-regulation and
stabilization of respiratory chain super-complexes, resulting in partial rescue of the clinical phenotype.
Key words: assembly factor, complex I, exercise intolerance, mitochondrial, MTND1.
INTRODUCTION
Isolated deficiencies of human complex I (CI) often cause severe
early-onset progressive disease, but the spectrum of disorders
associated with this biochemical abnormality is expanding. In
particular, mutations in the ND1 subunit of CI [MIM #252010]
are associated with Leigh syndrome [MIM #256000]; cardi-
omyopathy; epilepsy; encephalopathy; mitochondrial encepha-
Abbreviations: 31P-MRS, phosphorus magnetic resonance spectroscopy; ACTB, β -actin; AFG3L2, AFG3-like AAA ATPase 2; AT, anaerobic threshold; BN, blue native;
CI/CII/CIII/CIV/CV, complex I/II/III/IV/V; CIII2, CIII dimer; COX, cytochrome c oxidase; CPET, cardiopulmonary exercise testing; H&E, haematoxylin and eosin; HSP60, heat shock
protein 60; LHON, Leber hereditary optic neuropathy; LonP1, Lon peptidase 1; MELAS, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes; MRC, Medical
Research Council; NDUFA9, NADH dehydrogenase (ubiquinone) 1α sub-complex 9; NDUFAF, NADH dehydrogenase (ubiquinone) complex I assembly factor; NDUFB8, NADH
dehydrogenase (ubiquinone) 1β sub-complex 8; PCr, phosphocreatine; POTS, postural orthostatic tachycardia syndrome; RRF, ragged-red fibre; SDH, succinate dehydrogenase; SDHA,
succinate dehydrogenase complex subunit A; VO2 peak, peak oxygen consumption; VO2, oxygen uptake
1 These authors contributed equally towards this work.
2 Present address: Institute of Vegetative Physiology, University of Cologne, Cologne, Germany.
Correspondence: Professor Rob Taylor (email robert.taylor@ncl.ac.uk).
lomyopathy, lactic acidosis and stroke-like episodes (MELAS)
[MIM #54000]; Leber hereditary optic neuropathy (LHON)
[MIM #535000] and an overlap syndrome comprising clinical
features of both LHON and MELAS [1–7]. Exercise intolerance
is a common symptom of mitochondrial disorders that can occur
in isolation or as part of a multi-system disorder and has been
associated with mutations in many genes encoding subunits of
various complexes [8–11]. However, the relationship between the
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pathogenicmtDNAmutation and the biochemical and phenotypic
expression of the defect remains poorly understood.
In the present paper, we describe two unrelated adult pa-
tients with severe isolated CI deficiency in skeletal muscle,
progressive exercise intolerance, myopathy (without cardiomy-
opathy) and persistent lactic acidaemia. Both patients harbour
novel heteroplasmic MTND1 (NADH dehydrogenase subunit
1) gene [MIM #516000] mutations. We have characterized
VO2 (oxygen uptake) kinetics during graded aerobic exer-
cise, assessed in vivo mitochondrial function using phosphorus
MR spectroscopy and evaluated the molecular mechanisms
underlying this purely muscular phenotype to understand the im-
pact of both mutations on CI biogenesis.
MATERIALS AND METHODS
Study approval
Local study approval was granted (NRES Committee North East-
Newcastle & North Tyneside 1) and written informed consent
from both patients was obtained prior to study inclusion. All
clinical investigations were evaluated according to the Declara-
tion of Helsinki.
Subjects
Patient 1 presented at age 16 years with mild exercise intolerance
and prominent fatigue following a viral illness. She was diag-
nosedwith chronic fatigue syndrome. At age 25 years she presen-
ted with progressive exertion-related dyspnoea and palpitations
and was provisionally diagnosed with asthma. By 28 years of
age, muscle weakness and fatigue with exercise-induced head-
ache, vomiting, cardiac palpitations and syncope were prominent
and a metabolic acidosis with elevated serum lactate was detec-
ted (Table 1). At this stage a neuromuscular opinion was sought.
The clinical picture has progressed rapidly over the last 2 years
with exercise tolerance reduced to less than 50 m. She has de-
veloped alcohol intolerance and postural orthostatic tachycardia
syndrome (POTS). Patient 2 presented at age 22 years of age to a
neurologist with life long indolent exertion-related muscle weak-
ness and pain, dyspnoea, cardiac palpitations and syncope. There
was no family history ofmuscle disease or parental consanguinity
in either case.
Cardiopulmonary exercise testing
Cardiopulmonary exercise testing (CPET) was performed in both
subjects as described elsewhere [12]. Anaerobic threshold (AT)
was determined using the V-slope method, as previously de-
scribed [13].
Phosphorus magnetic resonance spectroscopy
Muscle phosphorusmagnetic resonance spectroscopy (31P-MRS)
was performed on the left calf, as detailed previously, in Patient
1 to evaluate in vivo mitochondrial function relative to an age
matched reference group [14].
Histochemical and biochemical analyses
Standard histological [H&E (haematoxylin and eosin), modified
Gomori trichrome] and histochemical analyses of skeletal muscle
biopsies were performed on fresh-frozen skeletal muscle sections
(10 μm) [15]. Mitochondrial respiratory chain complex activities
were determined in skeletal muscle homogenates and expressed
relative to the activity of the matrix marker enzyme citrate syn-
thase [16].
Molecular genetics
Total DNAwas extracted from available tissues includingmuscle,
blood, buccal epithelia, urinary sediments, culturedmyoblasts and
fibroblasts. Muscle mtDNA rearrangements were investigated by
long-range PCR strategies [17]. Direct sequencing of the en-
tire mtDNA genome was undertaken [18]; alignment and variant
calling were performed using SeqScape software (v2.1.1, Ap-
plied Biosystems) comparing changes to the GenBank reference
sequence for human mtDNA (accession number NC_012920.1).
Assessment of mtDNA mutation load by
quantitative pyrosequencing
Heteroplasmic levels of the m.3365T>C and m.4175G>Amuta-
tions were determined in homogenate tissue and individual laser-
microcapturedCOX-positive andCOX-positive ragged-red fibres
(RRFs) by quantitative pyrosequencing. Quantification of the het-
eroplasmy level of each variant was achieved using Pyromark
Q24 software [19].
Mitochondrial respiratory chain complex subunit
immunohistochemistry
Complex subunit immunohistochemistry was carried out on
frozen tissue sections as described previously [20]. Primary an-
tibodies and their dilutions used were: CI ND1, 1:200 (gift from
Dr Anne Lombes), CI NDUFB8 1:50, CII SDHA (succinate de-
hydrogenase complex subunit A; 70 kDa flavoprotein subunit)
1:1000, CIII UQCRC2 (ubiquinone: cytochrome c reductase core
protein 2) (Core 2) 1:1000, CIV MTCO1 (mitochondrial cyto-
chrome c oxidase subunit 1) 1:1000, CIVMTCO4, 1:1000, Porin,
1:1000; all commercially available antibodies were purchased
from Abcam. Primary antibodies were detected using a poly-
mer detection system (Menarini Diagnostics) as per the manu-
facturer’s instructions and visualized with 3,3′-diaminobenzidine
(DAB; Sigma).
BN/PAGE and SDS/PAGE
For BN (blue native)/PAGE, frozen skeletal muscle (10–50 mg)
was homogenized and solubilizedwith 2% dodecylmaltoside (in-
dividual complexes and smaller super-complexes) or 4% digit-
onin (super-complexes) [21] and electrophoresed through precast
4–16% (dodecylmaltoside) or 3–13% gels (Invitrogen). Activ-
ities of CI, CII and CIV were estimated by in-gel assays as de-
scribed in [22]. For 2D analysis, 1D lanes were incubated for
15 min in 1% SDS and 1% β-mercaptoethanol and separated in
a 16% Tricine/SDS gel (BN-SDS/PAGE). For SDS/PAGE, pro-
teins were extracted from enriched membranes (muscle) and sep-
arated by standard SDS/PAGE procedures. Proteins were trans-
ferred onto PVDF membranes (GE Healthcare) and processed
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for immunoblotting. Primary antibodies used were: NDUFB8
[NADH dehydrogenase (ubiquinone) 1β sub-complex 8],
NDUFA9 [NADH dehydrogenase (ubiquinone) 1α sub-complex
9], Core2 (complex III Core protein 2), COXI, COXII, SDHA,
CV subunits, TOM20 (translocase of outer mitochondrial
membrane 20 kDa subunit) and porin (MitoSciences); AFG3L2
(AFG3-like AAAATPase 2; Proteintech); LonP1 (Lon peptidase
1) and NDUFAF3 [NADH dehydrogenase (ubiquinone) complex
I assembly factor; Sigma Life Science]; HSP60 (heat shock pro-
tein 60; BD Biosciences); NDUFAF1 and NDUFAF2 (gifts from
Professor Leo Nijtmans) and ND1 (gift fromDr A. Lombes). An-
tibodies were detected with appropriate horseradish peroxidase
(HRP)-conjugated immunoglobulins (Dako) and chemilumines-
cence detection reagents (GE Healthcare).
Quantitative real-time PCR
Total RNA from control (n= 4) and patient muscle was ex-
tracted using TRIrizol Reagent (Life Technologies) and re-
verse transcribed (0.5–1 μg) with random hexamers (Super-
script III First Strand Synthesis System, Life Technologies).
Levels of mRNA expression of NDUFAF1 [MIM #606934],
NDUFAF2 [MIM #609653], NDUFAF3 [MIM #612911] and
ACTB (β-actin) [MIM #102630] were assessed in triplicate by
real-time PCR using commercially-available TaqMan assays (as-
say IDsHs00211245_m1, Hs02380072_u1, Hs00404252_g1 and
Hs01060665_g1 respectively; Life Technologies). After normal-
ization to ACTB, average expression levels of the CI assembly
factor genes in patients were reported relative to control values,
with differences assessed using a two-tailed Student’s t test.
RESULTS
Clinical features
Patient 1
Patient 1 was of normal intelligence (Wechsler test of adult
reading: thirty-seventh percentile), normal stature (1.7 m) and
body habitus (68.7 kg). She had no ptosis and eye movements
were normal. She did not have significant demonstrable clin-
ical weakness at rest [Medical Research Council (MRC) 5/5];
however, subtle upper and lower limb proximal weakness (MRC
4+/5) was evident followingminimal exertion (marching in place
ten times). She also displayedmarked evidence of increased vent-
ilator rate (>30 breaths/min), sinus tachycardia (>120 beats/min)
and bluish-hue discolouration to her digits. Therewas no evidence
of a dysautonomia and no cardiac or respiratory muscle involve-
ment. There was a persistent metabolic acidosis (serum bicarbon-
ate 9–19 mmol/l; normal range 22–29 mmol/l), a high random
serum lactate concentration [7.2–8.9 mmol/l; normal range <
1.7 mmol/l), markedly increasing post exertion up to 15.5 mmol/l
and normal total creatine kinase activity (52–76 units/l; normal
range <200 units/l). At the age of 27 years, there was electro-
physiological evidence of a significant proximal myopathy with
no findings of neuropathy. Conventional echocardiogram and car-
diac MRI revealed no cardiac muscle abnormalities. She was
treated with riboflavin (50 mg three times a day), high dose
co-enzyme Q10 (500 mg/day) and L-carnitine supplements with
minimal symptomatic or objective improvement. Current treat-
ment strategies include energy conservation with the use of a
wheelchair and pharmacological management with ivabradine
for POTS.
Patient 2
Patient 2 was of normal height (1.68 m) but thin body habitus
(47 kg). He had subtle unilateral ptosis and eye movements were
normal. His skeletal muscles were generally poorly developed
but he did not have significant demonstrable clinical weakness at
rest (MRC 5/5); however, subtle upper and lower limb proximal
weakness (MRC 4+/5) was evident following moderate exertion
(marching in place 20 times). There was no evidence of car-
diac or respiratory muscle involvement. There was a persistently
high resting serum lactate concentration (4.1–6.8 mmol/l; normal
range <1.7 mmol/l), increasing post exertion [15.4 mmol/l; cyc-
ling for 5 min; peak power 53W; peak oxygen consumption (VO2
peak) 14 ml/min per kg; AT 22% predicted VO2 peak] and raised
total creatine kinase activity (351–486 units/l; normal range <
320 units/l). Electrophysiological changes at the age of 11 years
were compatible with a myopathy with no findings of neuropathy.
CPET
VO2 peak, peak work capacity (power; W), AT and absolute AT
(expressed as a percentage of predicted peak VO2; ATVO2), were
markedly decreased in both subjects (Table 1). Plasma lactate
concentrations were concomitantly raised during CPET (Patient
1: resting lactate: 4.4 mmol/l, peak lactate: 13.2 mmol/l; Patient
2: resting lactate: 6.8 mmol/l, peak lactate: 15.4 mmol/l), with
slow lactate decay time to baseline (Patient 1: 60 min, Patient 2:
40 min).
31P-MRS shows significant mitochondrial energy
defects associated with isolated CI deficiency
31P-MRS examination showed that the ability of Patient 1’s
muscle to reduce phosphocreatine (PCr) and accumulate ADP
during exercise was normal. However, in recovery from muscle
contraction, the main indicators of mitochondrial function
demonstrated a severe impairment in oxidative metabolism
(Table 1).
Characterization of isolated complex I deficiency in
skeletal muscle biopsies
Oxidative enzyme reactions [succinate dehydrogenase (SDH) and
cytochrome c oxidase (COX)] revealed numerous fibres with
increased activity at the fibre periphery, confirmed by modified
Gomori trichrome staining which showed sub-sarcolemmal ac-
cumulations typical of ‘ragged-red’ changes affecting >25% of
all fibres in both patients (Figure 1A). Mitochondrial respiratory
chain enzyme studies revealed isolated CI deficiency in skeletal
muscle from both patients (Table 1), including a repeat muscle
biopsy obtained from Patient 1 taken 2 years after her initial
diagnostic biopsy. The biochemical defect in this patient was
not expressed in cultured myoblasts (results not shown). Muscle
analyses of Patient 1, shown in the present study, were performed
on the first muscle biopsy. The activities of all other respiratory
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Table 1 Peak exercise parameters, 31P-MRS examination on calf evaluating in vivomitochondrial function and assessment
of respiratory chain complex activities in skeletal muscle homogenates
BPM, beats per min; DCPIP, 2,6-dichlorophenol-indophenol; n/a, not available; t1/2 PCR (s), half time for PCR recovery from
end exercise to baseline concentrations; VO2, oxygen uptake. Enzyme activities are expressed as nmol of NADH oxidized/min
per unit of citrate synthase (CS) for CI, nmol of DCPIP reduced/min per unit of CS for CII (succinate:ubiquinone-1 reductase)
and the apparent first-order rate constant/s per unit of CS for CIII and CIV (×103).
Parameter Patient 1 Patient 2 Reference data (means +− S.D.)
CPET
Peak exercise data Absolute value (% of predicted) Absolute value (% of predicted) n/a
Heart rate (BPM) 172 (89) 180 (92) n/a
VO2 (ml/min) 0.575 (27) 0.638 (22) n/a
VO2 (ml/min per kg) 8 (27) 14 (22) n/a
VO2 (% of predicted VO2) 27 22 n/a
Power (W) 35 (21) 53 (27) n/a
AT
ATVO2 (ml/min per kg) 6 10 n/a
ATVO2 (% of predicted peak VO2) 20 16 n/a
ATVO2 (% of recorded peak VO2) 75 74 n/a
31P-MRS [14]
End exercise data
t1/2 PCr 52.5 n/a 29.2 +− 3.1
t1/2 ADP 31.4 n/a 20 +− 1
Respiratory chain complex activities Biopsy 1 Biopsy 2 Biopsy Controls (n= 25)
CI/CS 0.018 0.009 0.001 0.104 +− 0.036
CII/CS 0.092 0.127 0.070 0.145 +− 0.047
CIII/CS 0.673 1.790 0.634 0.554 +− 0.345
CIV/CS 0.834 1.394 1.216 1.124 +− 0.511
chain complexes were normal, confirming an isolated CI defi-
ciency (Table 1). This was further confirmed by muscle immuno-
histochemistry in Patient 1 in which expression of both mtDNA-
encoded (ND1) and nuclear-encoded (NDUFB8) CI structural
components was markedly decreased in or absent from a vast
number (>80%) of all muscle fibres (see Figures 1B,i and 1B,ii);
protein components of CII, CIII and CIV showed normal expres-
sion (Figure 1B).
Identification of novel pathogenic MTND1
mutations
Having excluded mtDNA rearrangements, we determined the
mtDNA sequence in muscle from both patients identifying novel
candidate pathogenic MTND1 mutations; Patient 1 harboured
a novel m.3365T>C variant [predicting p.(Leu20Pro)] which
was present at high levels of heteroplasmy (82% in biopsy 1;
86% in biopsy 2) in skeletal muscle, but undetectable in all
other tissue samples tested (Figures 2A and 2B). Patient 2 was
shown to harbour a novel m.4175G>A MTND1 variant predict-
ing p.(Trp290*) and premature truncation of the ND1 protein.
Quantitative pyrosequencing showed that the m.4175G>Amuta-
tion was present at high levels of heteroplasmy in skeletal muscle
(90% mutant load); at low levels (5% mutant load) in a urin-
ary sediment-derived DNA sample, but undetectable in all other
DNA samples (Figure 2C). Concurrent studies in the mothers
of both patients failed to detect the respective mtDNA mutation
suggesting de novo mutation events.
The m.3365T>C and m.4175G>Amutations were not previ-
ously reported on online databases of pathogenic mtDNA muta-
tions [23,24] or within our own database of>980 humanmtDNA
sequences. Using quantitative pyrosequencing, we detected a
trend towards higher levels of the m.3365T>C mutation in RRF
(72.2+− 24.4%, n= 10) than non-RRF (56.5+− 28.8%, n= 10,
P = 0.2049, two-tailed Student’s t test). For the m.4175G>A
mutation, significantly higher levels of mutation were detected in
COX-positive RRF (89.0+− 24.2% n= 21) than in COX-positive
non-RRF (39.6+− 44.2%, n= 11) (P= 0.0025, two-tailed Stu-
dent’s t test), confirming segregation of the m.4175A genotype
with a histopathological abnormality.
MTND1 mutations are associated with loss of
immunoreactive CI subunits and impaired CI
assembly
The m.3365T>C; p.(Leu20Pro) mutation is located within the
first transmembrane domain of the ND1 protein, whereas the
m.4175G>A; p.(Trp290*) mutation occurs within the hydro-
philic loop that faces the mitochondrial matrix between trans-
membrane domains G and H (Figure 2D). Western blot analysis
of muscle from both patients failed to detect ND1 protein and
identified markedly decreased levels of the nuclear-encoded CI
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Figure 1 (A) Histological and histochemical assessment of patient muscle biopsies and (B) immunohistochemical
analyses of muscle mitochondrial respiratory chain components in Patient 1
(A) Serial cryosections from both patients were assessed histologically (H&E and modified Gomori trichrome) and his-
tochemically for oxidative enzyme activities including SDH and COX. Histological analysis of Patient 2’s biopsy revealed
moderate variation in fibre size with abundant, slightly hypotrophic, fibre clusters showing sub-sarcolemmal and granular
sarcoplasmic basophilia and occasional fibres with internal nuclei. Both the histochemical reaction and the modified
Gomori trichrome staining confirmed sub-sarcolemmal mitochondrial accumulation typical of RRF ‘ragged-red’ fibres in
both subjects. (B) i, CI ND1 subunit; ii, CI NDUFB8 subunit; iii, CII 70 kDa flavoprotein subunit; iv, CIII core protein 2; v,
CIV subunit 1; vi, CIV subunit 4; viii, porin; viii, no primary antibody control. Immunocytochemical studies confirm very low
expression of both CI-encoded subunits (NDUFB8 and ND1), whereas there was normal immunoreactivity to the structural
components of all other mitochondrial respiratory chain complexes.
subunit NDUFB8, whereas steady-state levels of other respir-
atory chain complex structural subunits were unaffected (Fig-
ures 3A and 3B). BN/PAGE analysis with subsequent Western
blot analyses showed a fully assembled CI could be detected
in both patients, albeit at very low levels, whereas steady-state
levels of fully-assembled CII, CIII and CIV appeared unchanged
(Figure 3C). This observation was accurately reflected in the
in-gel activity assays which indicated some residual CI activ-
ity (Figure 3D), in agreement with immunocytochemical studies
(Figure 1B).
BN/PAGE, followed by Western blot and in-gel-activity
analyses of control muscle samples, showed a small amount of
fully assembled CI in its monomeric form, whereas the majority
of assembled complex was associated with other complexes
building the SC2 (supercomplex 2) [CI + CIII2 (CIII dimer)]
and SC3 (CI + CIII2 + CIV(1–4)) super-complexes (Figure 3E).
Levels of fully assembled CI were strongly decreased in patient
samples, with residual CI associated, in the most part, with CIII
in the SC2 (CI+CIII2) super-complex (Patient 1) and with CIV
in the SC3 (CI + CIII2 + CIV(1–4)) super-complex (Patient 2;
Figures 3E and 3F).
MTND1 mutations stimulate an increase in CI
assembly factor expression
We evaluated the steady-state levels of different CI assembly
factors including NDUFAF3 (early-stage factor), NDUFAF1 (in-
volved in the middle stages) and NDUFAF2 (involved in the late
stages of CI assembly) and mitochondrial proteases including
AFG3L2, LonP1 and HSP60. We observed no changes in the
expression levels of any proteases; however, steady-state levels
of all three CI assembly factors were markedly increased in pa-
tient muscle samples suggestive of a compensatory response to
the ND1 defect (Figure 4A). Confirmatory real-time PCR analy-
ses showed increased NDUFAF1 [MIM #606934], NDUFAF2
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Figure 2 mtDNA sequencing reveals novel mutations in the MTND1 gene
(A) Sequencing of the mitochondrial genome identified an m.3365T>C mutation in Patient 1 predicting a p.(Leu20Pro)
amino acid substitution. The mutation was present at high levels in patient muscle, but undetectable in all other tissue
samples and maternal samples, consistent with a de novo mutation event. (B) Evolutionary sequence alignment of the
relevant portion of the ND1 protein confirms p.Leu20 to be a highly conserved residue. (C) Sequencing of the mitochondrial
genome identified an m.4175G>A mutation in Patient 2 predicting a p.(Trp290*) truncating event. This heteroplasmic
mutation was present at high levels in patient muscle and at low levels in urinary sediment, but was also undetectable
in available maternal DNA samples. (D) Predicted structure of human ND1 showing the eight transmembrane domains
(http://sosui.proteome.bio.tuat.ac.jp) and the location of the p.(Leu20Pro) and p.(Trp209*) mutations, one within a
transmembrane region and one within a conserved hydrophilic extra-membrane loop.
[MIM #609653] andNDUFAF3 [MIM #612911] transcript levels
in patient muscle (Figure 4B).
BN-SDS/PAGE analysis of digitonin-solubilized control and
patient muscle samples showed that the majority of NDUFA9
was associated with the SC2 (CI + CIII2) and SC3 (CI + CIII2
+ CIV(1–4)) super-complexes in controls (Figure 4C). Both ND-
UFAF1 and NDUFAF2 were undetectable in control muscle. In
the patient muscle samples, the majority of NDUFA9 was de-
tected in association with the SC2 (CI + CIII2) and SC3 (CI
+ CIII2 + CIV(1–4)) super-complexes. However, smaller sub-
complexes were also observed in both patients. We found that
NDUFAF1 was associated with two complex I intermediates of
∼500 and ∼800 kDa, whereas NDUFAF2 was detected within
higher-molecular-mass associations corresponding to complexes
of 800 and 1500 kDa in muscle of both patients (Figure 4C). In
the patient samples, we observed higher amounts of CV in higher
supramolecular organizations (as dimer V2 and tetramer V4;
Figure 4C), whereas the majority of mt-ATP synthase was found
as monomers in controls.
DISCUSSION
We describe novel sporadic MTND1 mutations in two unrelated
patients with isolated CI deficiency characterized clinically by
marked exercise intolerance and in vivo mitochondrial dysfunc-
tion. The clinical phenotypes, severity of the biochemical defect
and the relatively indolent nature of the disease are conspicuously
similar in both patients. Neurological examination was essen-
tially normal in the resting state; however, response to exercise
in both cases was indicative of a mitochondrial myopathy. Both
cases highlight the importance of serum lactate testing in cases of
persistent unexplained exertional weakness or dyspnoea. Indeed,
mitochondrial disorders are recognized as a common cause of
referral for unexplained dyspnoea, with a period prevalence of
up to 8.5% [25].
Several strands of evidence indicate that the MTND1 muta-
tions are pathogenic, causing the clinical phenotype. The
m.3365T>C and m.4175G>A mutations are novel and absent
from available databases of characterized mtDNA mutations,
whereas bothMTND1 variants were heteroplasmic and segregate
with disease in muscle and, for Patient 2, with the histopatholo-
gical abnormality (COX-positive RRF). The undetectable steady-
state levels of ND1 protein suggest that both MTND1 mutations
affect production and/or stability of the protein with dramatic
effects on CI assembly and degradation of other CI subunits,
including NDUFB8. Intriguingly, ND1 protein deficiency does
not totally preclude assembly of the holocomplex, similar to that
observed in a patient with progressive encephalopathy due to a
B17.2L (NDUFAF2) [MIM #609653] null mutation [26].
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Figure 3 MTND1 mutations lead to a loss of immunoreactive CI subunits and impair CI assembly
(A) SDS/PAGE and Western blot analysis of muscle lysates (20 μg) from two controls (Co1, Co2) and two patients (P1,
m.3365T>C mutation; P2, m.4175G>A mutation). Membranes were probed with antibodies directed against mitochon-
drial respiratory chain subunits and porin as a loading control. (B) Relative protein expression levels. Band intensity of
indicated protein is normalized to band intensity of the loading control porin. Shown are mean values of three independent
experiments +− S.D. *P< 0.05 relative to controls; ns, not significant. (C) BN/PAGE of dodecyl maltoside (DDM)-solubilized
muscle samples (75 μg) from two controls (Co1, Co2) and both patients with MTND1 mutations (P1, P2) followed by West-
ern blot analysis. Membranes were probed with anti-NDUFA9 for CI, SDHA for CII, CORE2 for CIII2 and COX4 for CIV. Blots
are representative of two independent experiments. (D) In-gel enzyme activity (IGA) assay of respiratory chain complexes.
BN/PAGE was performed on DDM-solubilized muscle samples (150 μg) from two controls and both patients. Enzyme activ-
ities for CI, CIV and CII were examined. (E) BN/PAGE of digitonin-solubilized muscle samples (100 μg) from two controls
(Co1, Co2) and both patients (P1, P2) followed by Western blot analysis. Membranes were probed with anti-NDUFA9 and
with anti-CORE2. SC1, CIII2 + CIV; SC2, CI + CIII2; SC3, CI + CIII2 + CIV. Blots are representative of two independent
experiments. (F) IGA assay of mitochondrial super-complexes. BN/PAGE was performed on digitonin-solubilized muscle
samples (200 μg) from two controls and the two patients with MTND1 mutations (P1, P2). Enzyme activities for CI and CII
were examined. SC1, CIII2 + CIV; SC2, CI + CIII2; SC3, CI + CIII2 + CIV.
Smaller CI subunits were also detectable with several inter-
mediate complexes clearly seen in association with CI assembly
factors. Accumulation of stalled intermediates of ∼500 kDa and
∼800 kDa has previously been reported in patients with various
CI assembly pathway mutations who also exhibit reduced as-
sembly of the holoenzyme complex [26–31]. Steady-state levels
of the mitochondrial quality-control machinery including the
AAA protease AFG3L2, LonP1 protease and HSP60 remained
C© The Authors Journal compilation C© 2015 Biochemical Society 901
G.S. Gorman and others
Figure 4 (A and B) MTND1 mutations stimulate an increase in CI assembly factor expression and (C) 2D BN/PAGE
analysis of muscle mitochondria identifies smaller CI sub-complexes associated with MTND1 mutation
(A) SDS/PAGE and Western blot analysis of muscle lysates (20 μg) from two controls (Co1, Co2) and both patients
(P1, m.3365T>C mutation; P2, m.4175G>A mutation). Membranes were probed with antibodies directed against the
CI assembly factors NDUFAF1, NDUFAF2 and NDUFAF3, the mitochondrial AAA protease AFG3L2, the LonP1 protease,
the HSP60 and porin as a loading control. Blots are representative of two independent experiments. (B) Relative mRNA
expression levels of three CI assembly factor genes. The mRNA expression levels of NDUFAF1, NDUFAF2 and NDUFAF3
were measured by real-time PCR in Patients 1 and 2 and controls (n= 4) and normalized to ACTB mRNA levels. Average
patient data from three replicate experiments are expressed relative to control values +− S.D. *P< 0.015; **P< 0.001
relative to controls. (C) Digitonin-solubilized mitochondrial complexes were separated by 1D BN/PAGE, followed by 2D
Tricine-SDS/PAGE and Western blot analysis. Membranes were probed with SDHA for CII, α subunit for CV, NDUFA9 for
CI and NDUFAF1 and NDUFAF2. SC1, CIII2 + CIV; SC2, CI + CIII2; SC3, CI + CIII2 + CIV. The smaller sub-complexes
observed in both patients are highlighted by the ellipses; NDUFAF1 was associated with two CI intermediates of ∼500
and ∼800 kDa, whereas NDUFAF2 was detected within higher-molecular-mass associations corresponding to complexes
of 800 and 1500 kDa in the muscle of Patients 1 and 2.
unchanged in association with up-regulation of assembly factor
for intermediate-stage (NDUFAF1) and late-stage (NDUFAF2)
CI assembly in patient muscle, suggesting a shift in this dynamic
equilibrium state that favours assembly and stability of respirat-
ory complex formation over degradation.
We speculate that mutation load and tissue-specific ef-
fects in CI formation and stability, mediated through assembly
factor up-regulation, act as a compensatory response to the
deleteriousMTND1 genetic defect, with an absence of secondary
defects in CII, CIII and CIV further facilitating complex stabil-
ization. Taken together, our findings all support assembly factor
up-regulation in isolated CI deficiency as an adaptive process to
stabilize the respiratory complexes, a phenomenon not previously
reportedwithMTND1mutations [32] and that the pathogenic role
of these mutations at a molecular level is dependent on the stage
of CI assembly. Mitotic segregation has long been recognized
902 C© The Authors Journal compilation C© 2015 Biochemical Society
Indolent exercise intolerance and novel MTND1 mutations
to contribute to phenotypic variability that may explain the isol-
ated muscle defects in these patients, although we concede that
definitive exclusion of CNS involvement cannot be definitively
made based on current evaluations.
In summary, we report two novelMTND1mutations that clin-
ically manifest as isolated exercise intolerance and at a molecu-
lar level cause assembly factor up-regulation and sub-complex
assembly acting to stabilize respiratory chain complexes and sal-
vage assembly of the holoenzyme complex.
CLINICAL PERSPECTIVES
 We sought to assess in vivo and vitro mitochondrial function
and evaluate the molecular mechanisms underlying a purely
muscular phenotype in two adults whose clinical pictures
were dominated by progressive exercise intolerance, lactic
acidaemia and severe isolated mitochondrial CI deficiency in
muscle.
 We describe the detailed clinical, physiological, biochemical
and molecular characterization of these patients who we show
to harbour novel heteroplasmic mutations in the mtDNA-
encoded MTND1 gene.
 We demonstrate for the first time that mitochondrial super-
complex reorganization occurs as a response to a compens-
atory mechanism to partially extricate the clinical phenotype
involving up-regulation of CI assembly factors, a phenomenon
not previously reported withMTND1 mutations.
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